Candel Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

CADL$9.35-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

COMMON STOCK · TREASURY STOCK
	SHARES	AMOUNT	SHARES	AMOUNT	ADDITIONALPAID-IN CAPITAL	ACCUMULATEDDEFICIT	STOCKHOLDERS’EQUITY
Balance as of December 31, 2022	29,042,418	$290	(122,608)	$(448)	$146,961	$(99,089)	$47,714
Stock-based compensation	—	—	—	—	3,137	—	3,137
Restricted stock unit vesting, net of shares withheld for taxes	171,209	—	—	—	(121)	—	(121)
Change in fair value of NC Ohio Trust Warrants	—	—	—	—	(46)	—	(46)
Net loss	—	—	—	—	—	(37,939)	(37,939)
Balance as of December 31, 2023	29,213,627	$290	(122,608)	$(448)	$149,931	$(137,028)	$12,745
Issuance of common stock and accompanying pre-funded warrants in public offering, net of issuance costs of $6.1 million	12,000,001	120	—	—	85,808	—	85,928
Sale of common stock through at-the-market offerings, net of issuance costs of $0.5 million	2,936,057	29	—	—	15,801	—	15,830
Options exercised	846,943	9	—	—	1,680	—	1,689
Stock-based compensation	—	—	—	—	4,170	—	4,170
Restricted stock unit vesting	1,936,460	21	—	—	(21)	—	—
Change in fair value of NC Ohio Trust Warrants	—	—	—	—	1,142	—	1,142
Net loss	—	—	—	—	—	(55,177)	(55,177)
Balance as of December 31, 2024	46,933,088	$469	(122,608)	$(448)	$258,511	$(192,205)	$66,327

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.